Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan

Montefiore Medicine Academic Health System

Status and phase

Completed

Phase 3

Conditions

Neuroendocrine Tumors

Treatments

Drug: 68Ga-DOTATOC

Study type

Interventional

Funder types

Other

Identifiers

NCT03136328

15-06-274

Details and patient eligibility

About

The primary goal of the analysis is to estimate the diagnostic accuracy of Gallium 68 (68Ga) -DOTATOC PET/CT for detecting neuroendocrine tumors (NETs) compared to conventional imaging techniques such as Magnetic Resonance Imaging (MRI) and Computerized Tomography (CT). Participants with histologically and/or clinically confirmed and/or suspected NET will be enrolled.

Full description

This is a prospective, Phase 2, single center study of participants with Neuroendocrine Tumors (NETs). Study participants will receive 68Ga-DOTATOC. DOTATOC is a somatostatin analogue that localizes on the somatostatin receptors expressed by NETs and is attached to a radioactive material called Gallium 68. Participants will undergo a PET/CT imaging study to investigate 68Ga-DOTATOC's suitability as a positron emission tomography (PET) imaging agent for NETs. The radiation (imaging) dose will be 111-185 megabecquerel (MBq) (3 - 5 mCi) ± 25%. All doses after labeling will be presented in buffered solution for intravenous injection. Imaging will start 90 ±30 minutes after injection.

Sensitivity and specificity of this imaging technique will be compared with those of conventional imaging modality including CT, MRI and In-111 Octreoscan performed within 6-12 months before or after PET/CT.

Enrollment

11 patients

Sex

All

Ages

18 to 99 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Signed informed consent.
Patients of either gender, aged ≥18 years.
Karnofsky status ≥60.
Life expectancy of at least 12 weeks.
Histologically and/or clinically confirmed and/or suspicious of NET.
A diagnostic CT or MRI of the tumour region or suspected area within the previous 12 weeks prior to dosing day is available.
Somatostatin-analogue scintigraphy scan with result (positive or negative) within the last 12 weeks.
Recent Blood test results up to 4-6 weeks as follows:
1. White Blood Cell (WBC): >2*109/L
2. Haemoglobin: >8.0g/Dl
3. Platelets: >50x109/L
4. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Alkaline phosphatase (AP) each less than, or equal to, 5 times its Upper Limit of Normal (ULN)
5. Bilirubin less than, or equal to, three times its ULN
Serum creatinine: within normal range or <120μmol/L for patients aged 60 years or older.
Negative pregnancy test in women capable of child-bearing.

Exclusion criteria

Known hypersensitivity to Gallium 68, DOTATOC or to any of the excipients of 68Ga-DOTATOC.
Therapeutic use of any somatostatin analogue, including Sandostatin® LAR (Long Acting Release) (within 28 days) and Sandostatin® (within 2 days) prior to study imaging. If a patient is on Sandostatin® LAR a wash-out phase of 28 days is required before the injection of the study drug.
Pregnant or breast-feeding women.
Current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study.